logo

For the Inventor, By the Inventor

Novato, CA, United States of America

Biomarin Pharmaceutical Inc.


USPTO Granted Patents = 136

% Expired Patents = 21.3



Trademarks = 21

Forward Citations = 1,148

Loading Chart...
Loading Chart...

146 inventors (with patents filed for the assignee):

goldMedal Augustus O Okhamafe (23 out of 29 patents)

silverMedal Daniel J Wendt (23 out of 23 patents)

bronzeMedal Emil D Kakkis (21 out of 45 patents)

4.  Jonathan LeBowitz (18 out of 23 patents)

5.  Michel Claude Vellard (16 out of 16 patents)

6.  Bing Wang (13 out of 64 patents)

7.  James R Rusche (13 out of 18 patents)

8.  Brett E Crawford (13 out of 15 patents)

9.  Charles A Glass (13 out of 20 patents)

10.  Mika Aoyagi-Scharber (12 out of 12 patents)

11.  Jillian R Brown (12 out of 14 patents)

12.  Vincent Jacques (11 out of 30 patents)

13.  Shinong Long (11 out of 11 patents)

14.  Norton P Peet (11 out of 87 patents)

15.  Melita Dvorak-Ewell (10 out of 10 patents)


Core Competencies:
C-Type Natriuretic Peptide
Lysosomal Enzyme
Adeno-Associated Virus
Phenylalanine Ammonia-Lyase
Histone Deacetylase Inhibitors
TPP-1 Formulations
Glucosylceramide Synthase Inhibitors
Metabolic Disorders
Skeletal Dysplasia
Osteoarthritis
Glycan Residual Compounds

136 patents:

1. 12514906 - Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia (2026-01-06),
2. 12239692 - Adeno-associated virus factor VIII vectors (2025-03-04),
3. 12233106 - C-type natriuretic peptide variants to treat skeletal dysplasia in children (2025-02-25),
4. 12214015 - Use of c-type natriuretic peptide variants to treat osteoarthritis (2025-02-04),
5. 12188058 - Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof (2025-01-07),
6. 12076372 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2024-09-03),
7. 11918633 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects (2024-03-05),
8. 11911446 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2024-02-27),
9. 11821008 - Liver targeting adeno-associated viral vectors (2023-11-21),
10. 11739345 - Methods of treating phenylketonuria (2023-08-29),
11. 11690898 - Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same (2023-07-04),
12. 11590204 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2023-02-28),
13. 11584780 - Adeno-associated virus capsid proteins (2023-02-21),
14. 11505790 - Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof (2022-11-22),
15. 11406690 - Adeno-associated virus factor VIII vectors (2022-08-09),
Biomarin Pharmaceutical Inc., headquartered in Novato, California, specializes in developing innovative therapies for rare genetic disorders. The company focuses on lysosomal enzyme therapy, leveraging advanced technologies such as C-Type Natriuretic Peptide and Adeno-Associated Virus to address metabolic disorders. Biomarin's research encompasses a range of core topics, including Phenylalanine Ammonia-Lyase and Glucosylceramide Synthase Inhibitors, aiming to improve patient outcomes through targeted treatment solutions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Biomarin Pharmaceutical Inc.
136 Patents

#1 in Novato, CA

#638 in California

#2,845 in US

#5,930 in the World

Novato, CA (US)
Novato, CA, United States of America

Biomarin Pharmaceutical Inc.

Forward Citations = 1,148

146 inventors:

goldMedal Augustus O Okhamafe (23 out of 29 patents)

silverMedal Daniel J Wendt (23 out of 23 patents)

bronzeMedal Emil D Kakkis (21 out of 45 patents)

4.  Jonathan LeBowitz (18 out of 23 patents)

5.  Michel Claude Vellard (16 out of 16 patents)

Please report any incorrect information to [email protected]
Loading…